Melanoma immunotherapy: historical precedents, recent successes and future prospects

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. (105), 273–290 (1893).
  Google Scholar
• 2  Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature480(7378),480–489 (2011).
  Medline CASGoogle Scholar
• 3  Park J, Wrzesinski SH, Stern E et al. Combination delivery of TGF-beta inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater.11(10),895–905 (2012).
  Medline CASGoogle Scholar
• 4  Woglom WH. Immunity to transplantable tumours. Cancer Res.4,129–138 (1929).
  Google Scholar
• 5  Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature172(4379),603–606 (1953).
  Medline CASGoogle Scholar
• 6  Baldwin RW. Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Br. J. Cancer9(4),652–657 (1955).
  Medline CASGoogle Scholar
• 7  Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res.13(12),835–837 (1953).
  Medline CASGoogle Scholar
• 8  Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res.20,1561–1572 (1960).
  Medline CASGoogle Scholar
• 9  Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst.18(6),769–778 (1957).
  Medline CASGoogle Scholar
• 10  Burnet FM. Immunological aspects of malignant disease. Lancet1(7501),1171–1174 (1967).
  Medline CASGoogle Scholar
• 11  Ehrlich P. [About the current state of cancer research]. Ned. Tijdschr. Geneeskd.5,273–290 (1909).
  Google Scholar
• 12  Arnold B, Schonrich G, Hammerling GJ. Multiple levels of peripheral tolerance. Immunol. Today14(1),12–14 (1993).
  Medline CASGoogle Scholar
• 13  Fowlkes BJ, Ramsdell F. T-cell tolerance. Curr. Opin Immunol.5(6),873–879 (1993).
  Medline CASGoogle Scholar
• 14  Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol.12,991–1045 (1994).
  Medline CASGoogle Scholar
• 15  Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol.12,337–365 (1994).
  Medline CASGoogle Scholar
• 16  Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med.183(3),725–729 (1996).
  Medline CASGoogle Scholar
• 17  Melief CJ, Toes RE, Medema JP, Van Der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv. Immunol.75,235–282 (2000).
  Medline CASGoogle Scholar
• 18  Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity10(3),281–287 (1999).
  Medline CASGoogle Scholar
• 19  Urban JL, Schreiber H. Tumor antigens. Annu. Rev. Immunol.10,617–644 (1992).
  Medline CASGoogle Scholar
• 20  Fenton RG, Longo DL. Genetic instability and tumor cell variation: implications for immunotherapy. J. Natl Cancer Inst.87(4),241–243 (1995).
  Medline CASGoogle Scholar
• 21  Stoler DL, Chen N, Basik M et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl Acad. Sci. USA96(26),15121–15126 (1999).
  Medline CASGoogle Scholar
• 22  Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med.183(1),283–287 (1996).
  Medline CASGoogle Scholar
• 23  Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol.24(3),605–610 (1994).
  Medline CASGoogle Scholar
• 24  Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med.1(12),1297–1302 (1995).
  Medline CASGoogle Scholar
• 25  Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.4(3),328–332 (1998).
  Medline CASGoogle Scholar
• 26  Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature410(6832),1107–1111 (2001).
  Medline CASGoogle Scholar
• 27  Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol.2(4),293–299 (2001).
  Medline CASGoogle Scholar
• 28  Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol. Cell Biol.81(2),106–113 (2003).
  Medline CASGoogle Scholar
• 29  Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med.5(6),677–685 (1999).
  Medline CASGoogle Scholar
• 30  Zeiser R, Schnitzler M, Andrlova H, Hellige T, Meiss F. Immunotherapy for malignant melanoma. Curr. Stem Cell Res. Ther.7(3),217–228 (2012).
  Medline CASGoogle Scholar
• 31  Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu. Rev. Immunol.24,175–208 (2006).
  Medline CASGoogle Scholar
• 32  Carlson BM. Human Embryology and Developmental Biology (3rd Edition). Elsevier Mosby, MO, USA (2004).
  Google Scholar
• 33  Odunsi K, Matsuzaki J, Karbach J et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl Acad. Sci. USA109(15),5797–5802 (2012).
  Medline CASGoogle Scholar
• 34  Slingluff CL Jr, Petroni GR, Olson W et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J. Clin. Oncol.26(30),4973–4980 (2008).
  MedlineGoogle Scholar
• 35  Tjin EP, Konijnenberg D, Krebbers G et al. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin. Cancer Res.17(17),5736–5747 (2011).
  Medline CASGoogle Scholar
• 36  Darrasse-Jeze G, Deroubaix S, Mouquet H et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med.206(9),1853–1862 (2009).
  Medline CASGoogle Scholar
• 37  Jiang A, Bloom O, Ono S et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity27(4),610–624 (2007).
  MedlineGoogle Scholar
• 38  Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol.21,685–711 (2003).
  Medline CASGoogle Scholar
• 39  Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med.191(3),411–416 (2000).
  Medline CASGoogle Scholar
• 40  Gray JC, Johnson PW, Glennie MJ. Therapeutic potential of immunostimulatory monoclonal antibodies. Clin. Sci. (Lond.)111(2),93–106 (2006).
  Medline CASGoogle Scholar
• 41  Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med.355(10),1018–1028 (2006).
  Medline CASGoogle Scholar
• 42  Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol.74,181–273 (2000).
  Medline CASGoogle Scholar
• 43  Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J. Clin. Oncol.29(36),4828–4836 (2011).
  Medline CASGoogle Scholar
• 44  Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19),12293–12297 (2002).
  Medline CASGoogle Scholar
• 45  Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J Med.366(10),883–892 (2012).
  Medline CASGoogle Scholar
• 46  Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev.188,22–32 (2002).
  Medline CASGoogle Scholar
• 47  Chen YT, Stockert E, Jungbluth A et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl Acad. Sci. USA93(12),5915–5919 (1996).
  Medline CASGoogle Scholar
• 48  Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med.366(26),2455–2465 (2012).
  Medline CASGoogle Scholar
• 49  Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366(26),2443–2454 (2012).
  Medline CASGoogle Scholar
• 50  Rosenberg SA, Eberlein TJ, Grimm EA, Lotze MT, Mazumder A, Rosenstein M. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery92(2),328–336 (1982).
  Medline CASGoogle Scholar
• 51  Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA271(12),907–913 (1994).
  Medline CASGoogle Scholar
• 52  Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7),2105–2116 (1999).▪ Systematic review of the literature on IL-2. Despite the modest complete remission rate in the largest clinical trials, the long duration of complete remission suggests a small subpopulation might benefit from IL-2.
  Medline CASGoogle Scholar
• 53  Petrella T, Quirt I, Verma S et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat. Rev.33(5),484–496 (2007).
  Medline CASGoogle Scholar
• 54  Mcdermott DF, Atkins MB. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. J. Clin. Oncol.25(25),3791–3793 (2007).
  Medline CASGoogle Scholar
• 55  Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J. Clin. Oncol.15(7),2579–2588 (1997).
  Medline CASGoogle Scholar
• 56  Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol.16(9),2921–2929 (1998).
  Medline CASGoogle Scholar
• 57  Ridolfi R, Chiarion-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter Phase III randomized clinical trial. J. Clin. Oncol.20(6),1600–1607 (2002).
  Medline CASGoogle Scholar
• 58  Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol.23(27),6747–6755 (2005).
  Medline CASGoogle Scholar
• 59  Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS. A Phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer113(7),1632–1640 (2008).
  Medline CASGoogle Scholar
• 60  Sabatino M, Kim-Schulze S, Panelli MC et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol.27(16),2645–2652 (2009).
  Medline CASGoogle Scholar
• 61  Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol Sci.147(927),258–267 (1957).
  Medline CASGoogle Scholar
• 62  Dummer R, Mangana J. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. Biologics3,169–182 (2009).
  Medline CASGoogle Scholar
• 63  Sen GC. Viruses and interferons. Annu. Rev. Microbiol.55,255–281 (2001).
  Medline CASGoogle Scholar
• 64  Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol.14(1),7–17 (1996).
  Medline CASGoogle Scholar
• 65  Eggermont AM, Suciu S, Mackie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet366(9492),1189–1196 (2005).
  Medline CASGoogle Scholar
• 66  Eggermont AM, Suciu S, Santinami M et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised Phase III trial. Lancet372(9633),117–126 (2008).
  Medline CASGoogle Scholar
• 67  Kirkwood JM. Adjuvant interferon in the treatment of melanoma. Br. J. Cancer82(10),1755–1756 (2000).
  Medline CASGoogle Scholar
• 68  Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst.102(7),493–501 (2010).
  Medline CASGoogle Scholar
• 69  Garbe C, Radny P, Linse R et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized Phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann. Oncol.19(6),1195–1201 (2008).
  Medline CASGoogle Scholar
• 70  Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol.16(4),1425–1429 (1998).
  Medline CASGoogle Scholar
• 71  Ascierto PA, Palmieri G, Parasole R, Daponte A, Castello G. 3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma. Int. J. Mol. Med.3(3),303–306 (1999).
  Medline CASGoogle Scholar
• 72  Rozati S, Naef L, Levesque MP, French LE, Dummer R. Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. J. Immunother.36(1),52–56 (2013).
  Medline CASGoogle Scholar
• 73  Eggermont AM, Suciu S, Testori A et al. Long-term results of the randomized Phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol.30(31),3810 (2012).▪ Largest randomized clinical trial on interferon adjuvant therapy that showed survival benefit in patients with sentinel node involvement and ulceration.
  Medline CASGoogle Scholar
• 74  Hodi FS, O’Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8),711–723 (2010).
  Medline CASGoogle Scholar
• 75  Shahabi V, Whitney G, Hamid O et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol. Immunother.61(5),733–737 (2012).
  Medline CASGoogle Scholar
• 76  Eggermont AM, Robert C. Melanoma in 2011: a new paradigm tumor for drug development. Nat. Rev. Clin. Oncol.9(2),74–76 (2012).
  Medline CASGoogle Scholar
• 77  Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial. Lancet Oncol.13(5),459–465 (2012).
  Medline CASGoogle Scholar
• 78  Tarhini AA, Kirkwood JM. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park)24(14),1302, 1304 (2010).
  MedlineGoogle Scholar
• 79  Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354(7),709–718 (2006).
  Medline CASGoogle Scholar
• 80  Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.15(23),7412–7420 (2009).
  Medline CASGoogle Scholar
• 81  Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin. Cancer Res.15(23),7116–7118 (2009).
  Medline CASGoogle Scholar
• 82  Gajewski TF, Hodi FS. Targeted Therapeutics in Melanoma. Humana, NY, USA (2012).
  Google Scholar
• 83  Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol.27(36),6199–6206 (2009).
  MedlineGoogle Scholar
• 84  Berd D, Maguire HC, Jr, Mccue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol.8(11),1858–1867 (1990).
  Medline CASGoogle Scholar
• 85  Hsueh EC, Essner R, Foshag LJ et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol.20(23),4549–4554 (2002).
  Medline CASGoogle Scholar
• 86  Dalgleish AG. Therapeutic cancer vaccines: why so few randomised Phase III studies reflect the initial optimism of Phase II studies. Vaccine29(47),8501–8505 (2011).
  MedlineGoogle Scholar
• 87  Morton DL, Mozillo N, Thompson JF et al. An international, randomized, Phase III trial of bacillus Calmette–Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J. Clin. Oncol.25(18S),8508 (2007).
  Google Scholar
• 88  Sosman JA, Sondak VK. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev. Vaccines2(3),353–368 (2003).
  Medline CASGoogle Scholar
• 89  Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Melanoma vaccines: developments over the past 10 years. Expert Rev. Vaccines10(6),853–873 (2011).
  Medline CASGoogle Scholar
• 90  Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity3(2),165–169 (1995).
  Medline CASGoogle Scholar
• 91  Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A Phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res.20(3),218–226 (2010).
  Medline CASGoogle Scholar
• 92  Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am.6(Suppl. 1),S11–S14 (2000).
  MedlineGoogle Scholar
• 93  Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8⁺ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115(3),739–746 (2005).
  Medline CASGoogle Scholar
• 94  Tacken PJ, Zeelenberg IS, Cruz LJ et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood118(26),6836–6844 (2011).
  Medline CASGoogle Scholar
• 95  Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol.38(5),1404–1413 (2008).
  Medline CASGoogle Scholar
• 96  Goldinger SM, Dummer R, Baumgaertner P et al. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur. J. Immunol.42(11),3049–3061 (2012).
  Medline CASGoogle Scholar
• 97  Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a Phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res.16(9),2646–2655 (2010).
  Medline CASGoogle Scholar
• 98  Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol.10(8),580–593 (2010).
  Medline CASGoogle Scholar
• 99  Yang JC, Rosenberg SA. Current approaches to the adoptive immunotherapy of cancer. Adv. Exp. Med. Biol.233,459–467 (1988).
  Medline CASGoogle Scholar
• 100  Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA90(2),720–724 (1993).
  Medline CASGoogle Scholar
• 101  Lake RA, Robinson BW. Immunotherapy and chemotherapy – a practical partnership. Nat. Rev. Cancer5(5),397–405 (2005).
  Medline CASGoogle Scholar
• 102  Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE4(3),e4749 (2009).
  MedlineGoogle Scholar
• 103  Junker N, Kvistborg P, Kollgaard T, Straten P, Andersen MH, Svane IM. Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cell. Immunol.273(1),1–9 (2012).
  Medline CASGoogle Scholar
• 104  Dudley ME. Adoptive cell therapy for patients with melanoma. J. Cancer2,360–362 (2011).
  MedlineGoogle Scholar
• 105  Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res.17(13),4550–4557 (2011).
  Medline CASGoogle Scholar
• 106  Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol. Immunother.57(11),1719–1726 (2008).
  Medline CASGoogle Scholar
• 107  Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl Med.3(95),95ra73 (2011).
  Medline CASGoogle Scholar
• 108  Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest.121(5),1822–1826 (2011).
  Medline CASGoogle Scholar
• 109  Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood114(3),535–546 (2009).
  Medline CASGoogle Scholar
• 110  Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med.8(8),793–800 (2002).
  Medline CASGoogle Scholar
• 111  Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4),252–264 (2012).
  Medline CASGoogle Scholar
• 112  Pierard GE, Aubin F, Humbert P. Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma? Dermatol. Res. Pract.2012,182157 (2012).
  MedlineGoogle Scholar
• 113  Fourcade J, Kudela P, Andrade Filho PA et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8⁺ T cells in melanoma patients. J. Immunother.31(8),781–791 (2008).
  Medline CASGoogle Scholar
• 114  Karbach J, Gnjatic S, Bender A et al. Tumor-reactive CD8⁺ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer126(4),909–918 (2010).
  Medline CASGoogle Scholar
• 115  Sierro SR, Donda A, Perret R et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur. J. Immunol.41(8),2217–2228 (2011).
  Medline CASGoogle Scholar
• 116  Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother.33(3),225–235 (2010).
  Medline CASGoogle Scholar
• 117  Li B, Vanroey M, Wang C, Chen TH, Korman A, Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor – secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin. Cancer Res.15(5),1623–1634 (2009).
  Medline CASGoogle Scholar
• 118  Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res.83,117–158 (2001).
  Medline CASGoogle Scholar
• 119  Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today18(2),89–95 (1997).
  Medline CASGoogle Scholar
• 120  Carretero R, Wang E, Rodriguez AI et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int. J. Cancer131(2),387–395 (2012).
  Medline CASGoogle Scholar
• 121  Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res.4(3),191–194 (1994).
  Medline CASGoogle Scholar
• 122  Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol.19(15),3477–3482 (2001).
  Medline CASGoogle Scholar
• 123  Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother.34(1),1–15 (2011).
  Medline CASGoogle Scholar
• 124  Scheel B, Braedel S, Probst J et al. Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol.34(2),537–547 (2004).
  Medline CASGoogle Scholar
• 125  Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796),126–129 (2006).
  Medline CASGoogle Scholar
• 126  Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol.29(7),917–924 (2011).
  MedlineGoogle Scholar
• 127  Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med.207(10),2187–2194 (2010).
  Medline CASGoogle Scholar
• 128  Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res.72(4),917–927 (2012).
  Medline CASGoogle Scholar
• 201  Phase II safety study of vemurafenib Followed by ipilimumab in subjects with V600 BRAF mutated advanced melanoma.http://clinicaltrials.gov/show/NCT01673854
  Google Scholar
• 202  Phase II randomized trial of ipilimumab versus ipilimumab and radiotherapy in metastatic melanoma.http://www.clinicaltrials.gov/ct2/show/NCT01689974
  Google Scholar
• 203  Phase 3 trial in subjects with metastatic melanoma xomparing 3 mg/kg ipilimumab versus 10 mg/kg ipilimumab.http://clinicaltrials.gov/show/NCT01515189
  Google Scholar
• 204  T-cell defined tumor antigens.http://cancerimmunity.org/peptide/
  Google Scholar
• 205  A Phase 3 pivotal trial comparing Allovectin-7^® alone vs chemotherapy alone in patients with stage 3 or stage 4 melanoma.http://clinicaltrials.gov/show/NCT00395070
  Google Scholar
• 206  BMS-936558 (MDX-1106) in subjects with advanced/metastatic clear-cell renal cell carcinoma (RCC).http://clinicaltrials.gov /show/NCT01354431
  Google Scholar
• 207  Phase I biomarker study (BMS-936558).http://clinicaltrials.gov /show/NCT01358721
  Google Scholar
• 208  Ph I/II ipilimumab vemurafenib combo.http://clinicaltrials.gov /show/NCT01400451
  Google Scholar